Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8806 |
High Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.8806 |
High Similarity |
NPD3620 |
Phase 2 |
0.8722 |
High Similarity |
NPD3027 |
Phase 3 |
0.8344 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.8268 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.8261 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8261 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8258 |
Intermediate Similarity |
NPD3705 |
Approved |
0.8162 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.8133 |
Intermediate Similarity |
NPD37 |
Approved |
0.811 |
Intermediate Similarity |
NPD228 |
Approved |
0.8102 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8092 |
Intermediate Similarity |
NPD4965 |
Approved |
0.8092 |
Intermediate Similarity |
NPD4966 |
Approved |
0.8092 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.8071 |
Intermediate Similarity |
NPD5735 |
Approved |
0.8056 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.8029 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7975 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7953 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7953 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7943 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7931 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7883 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7868 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7868 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7868 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7857 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7852 |
Intermediate Similarity |
NPD3092 |
Approved |
0.7842 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7793 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7746 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7718 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7698 |
Intermediate Similarity |
NPD4624 |
Approved |
0.7687 |
Intermediate Similarity |
NPD3091 |
Approved |
0.7671 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7671 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7667 |
Intermediate Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.766 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7639 |
Intermediate Similarity |
NPD6353 |
Approved |
0.7635 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.763 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7625 |
Intermediate Similarity |
NPD2489 |
Approved |
0.7625 |
Intermediate Similarity |
NPD27 |
Approved |
0.7622 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7619 |
Intermediate Similarity |
NPD7037 |
Approved |
0.7616 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.761 |
Intermediate Similarity |
NPD3051 |
Approved |
0.7591 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.759 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7574 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7574 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7568 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7568 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7562 |
Intermediate Similarity |
NPD2969 |
Approved |
0.7562 |
Intermediate Similarity |
NPD2970 |
Approved |
0.7554 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7551 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7548 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7547 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7534 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7517 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7517 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7483 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7483 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7482 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7482 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.747 |
Intermediate Similarity |
NPD7312 |
Approved |
0.747 |
Intermediate Similarity |
NPD7310 |
Approved |
0.747 |
Intermediate Similarity |
NPD4578 |
Approved |
0.747 |
Intermediate Similarity |
NPD7313 |
Approved |
0.747 |
Intermediate Similarity |
NPD4577 |
Approved |
0.747 |
Intermediate Similarity |
NPD7311 |
Approved |
0.7468 |
Intermediate Similarity |
NPD7833 |
Phase 2 |
0.7468 |
Intermediate Similarity |
NPD7832 |
Clinical (unspecified phase) |
0.7468 |
Intermediate Similarity |
NPD7831 |
Phase 2 |
0.7467 |
Intermediate Similarity |
NPD5241 |
Discontinued |
0.7466 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7466 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7466 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7463 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7462 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7455 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7453 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.745 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7447 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7445 |
Intermediate Similarity |
NPD3095 |
Discontinued |
0.744 |
Intermediate Similarity |
NPD4663 |
Approved |
0.7438 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7429 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7425 |
Intermediate Similarity |
NPD7309 |
Approved |
0.7425 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7417 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7413 |
Intermediate Similarity |
NPD7095 |
Approved |
0.741 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.74 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7397 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7396 |
Intermediate Similarity |
NPD7906 |
Approved |
0.7394 |
Intermediate Similarity |
NPD5736 |
Approved |
0.7394 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7391 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7389 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7389 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7378 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7368 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7362 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7361 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7357 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7353 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7351 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7329 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7324 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7319 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7319 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7319 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7315 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7305 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7301 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7301 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7301 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7299 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7297 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7296 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7296 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7285 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7285 |
Intermediate Similarity |
NPD6658 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD2801 |
Approved |
0.726 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.726 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.726 |
Intermediate Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.7255 |
Intermediate Similarity |
NPD7041 |
Phase 2 |
0.7255 |
Intermediate Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.7251 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD2161 |
Phase 2 |
0.7248 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.7246 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7246 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7244 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7244 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7241 |
Intermediate Similarity |
NPD6812 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7237 |
Intermediate Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.7237 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7237 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7234 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7234 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7233 |
Intermediate Similarity |
NPD2563 |
Approved |
0.7233 |
Intermediate Similarity |
NPD2560 |
Approved |
0.7219 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7212 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7208 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7208 |
Intermediate Similarity |
NPD7446 |
Clinical (unspecified phase) |
0.7206 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7197 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7194 |
Intermediate Similarity |
NPD4059 |
Approved |
0.7194 |
Intermediate Similarity |
NPD3019 |
Approved |
0.7192 |
Intermediate Similarity |
NPD6663 |
Approved |
0.7192 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7192 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7181 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7181 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7181 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7179 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7176 |
Intermediate Similarity |
NPD968 |
Approved |
0.717 |
Intermediate Similarity |
NPD5929 |
Approved |
0.717 |
Intermediate Similarity |
NPD6818 |
Clinical (unspecified phase) |
0.7163 |
Intermediate Similarity |
NPD2233 |
Approved |
0.7163 |
Intermediate Similarity |
NPD1840 |
Phase 2 |
0.7163 |
Intermediate Similarity |
NPD2232 |
Approved |
0.7163 |
Intermediate Similarity |
NPD2230 |
Approved |
0.7162 |
Intermediate Similarity |
NPD4579 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD6273 |
Approved |
0.716 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7133 |
Intermediate Similarity |
NPD4339 |
Clinical (unspecified phase) |
0.7123 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7123 |
Intermediate Similarity |
NPD3144 |
Approved |
0.7123 |
Intermediate Similarity |
NPD3145 |
Approved |
0.7119 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7114 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7113 |
Intermediate Similarity |
NPD1669 |
Approved |
0.7111 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7111 |
Intermediate Similarity |
NPD7635 |
Approved |
0.711 |
Intermediate Similarity |
NPD2488 |
Approved |
0.711 |
Intermediate Similarity |
NPD2490 |
Approved |
0.7105 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7103 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7097 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7092 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7092 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7091 |
Intermediate Similarity |
NPD4481 |
Phase 3 |
0.7075 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD8032 |
Phase 2 |
0.7073 |
Intermediate Similarity |
NPD6071 |
Discontinued |
0.7071 |
Intermediate Similarity |
NPD2932 |
Approved |
0.7063
|
Intermediate Similarity |
NPD5772 |
Approved |